ProQR Therapeutics NV (NASDAQ:PRQR) has been given a consensus recommendation of “Buy” by the eight research firms that are presently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, five have given a buy rating and two have assigned a strong buy rating to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $27.00.
PRQR has been the subject of a number of recent analyst reports. ValuEngine raised ProQR Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Thursday, November 28th. Zacks Investment Research raised shares of ProQR Therapeutics from a “hold” rating to a “strong-buy” rating and set a $10.00 price target on the stock in a research report on Wednesday, August 14th. Chardan Capital restated a “buy” rating and issued a $25.00 price objective on shares of ProQR Therapeutics in a research note on Friday, October 11th. Royal Bank of Canada reaffirmed a “buy” rating and set a $27.00 price objective on shares of ProQR Therapeutics in a report on Sunday, August 11th. Finally, BidaskClub upgraded shares of ProQR Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Thursday, November 21st.
Shares of PRQR stock traded down $0.43 during trading on Thursday, reaching $8.02. The company had a trading volume of 13,394 shares, compared to its average volume of 354,464. The firm’s 50 day simple moving average is $7.39 and its two-hundred day simple moving average is $8.47. ProQR Therapeutics has a one year low of $5.49 and a one year high of $19.94. The company has a debt-to-equity ratio of 0.18, a current ratio of 7.01 and a quick ratio of 7.01. The company has a market capitalization of $417.18 million, a PE ratio of -6.25 and a beta of 0.28.
ProQR Therapeutics Company Profile
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. Its lead product candidates include eluforsen, a RNA-based oligonucleotide used for the treatment of cystic fibrosis; QR-110, an oligonucleotide that is designed to treat Leber's congenital amaurosis; QR-313, a dermatology candidate for the treatment of epidermolysis bullosa; and QR-421a and QR-411 to treat type 2A Usher syndrome.
Read More: After-Hours Trading
Receive News & Ratings for ProQR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.